(“Ananda” or the “Company”)
CORPORATE UDPATE - CANNABIS CULTIVATION AND EXTRACTION
The directors of Ananda are pleased to provide the following update to shareholders.
Application for Home Office licence to grow >0.2% THC cannabis
Cannabis extraction and processing capability
As part of its plans to participate in the nascent medicinal and wellness cannabis sectors, Ananda believes that cannabis extraction and processing will emerge as a valuable business, as it has in other countries with more developed cannabis sectors.
To that end, DJT has acquired
DJT wants to ensure that it has flexibility in targeting various metabolites from cannabis and believes that the Vitalis CO2 extraction plant gives it that flexibility. This will enable it to provide feedstock for a wider array of products, potentially from its own cultivation as well as from third parties, as the medicinal and wellness cannabis sectors grow. The Directors believe that Vitalis is a global leader in industrial scale supercritical CO2 extraction systems for the production of high-quality CO2 extracts from cannabis plants.
As the medicinal cannabis markets grow and the CBD wellness market becomes increasingly regulated, Ananda believes that the ability to make high quality GMP compliant cannabinoid products, whether oil, distillates or isolates, will be increasingly important and as such, GMP compliant refining capacity will be increasingly valuable. As was experienced in the early days of the oil and gas industry, the Directors believe that refining capacity will be very valuable well into the maturing of the market. They also believe that the ability to be flexible in terms of end products will also be important as the market develops.
Ananda sees a number of options for the integration of the processing facilities into its medicinal and wellness cannabis growth plans. They include:
1. The production of GMP compliant cannabinoid oil, distillates and isolates to meet future medicinal and wellness cannabis demand in the
2. The production of GMP compliant cannabinoid oil, distillates and isolates to meet future medicinal and wellness cannabis demand globally in the event the regulatory and economic environment is advantageous in international markets. Under this scenario the plant would be located at an international location chosen for its position relative to supply and demand.
Over the coming months the retained pharmaceutical engineers will be working on developing plans to deliver on Ananda and DJT’s objectives. It is envisaged that the full funding of the acquisition of the plant, associated engineering and establishment costs and the employment of a skilled team to execute the plan, may be funded via debt secured against feedstock and offtake contracts for final product.
Aristaeus has been acquired by DJT for a consideration of £1 and the assumption of approximately £51,000 of debt, payable when DJT has sufficient funds. Aristaeus was established in
The Directors of the Company accept responsibility for the contents of this announcement.
ANANDA DEVELOPMENTS PLC+44 (0)7717 573 235 Chief Executive Officer firstname.lastname@example.org Melissa SturgessInvestor Relations Jeremy Sturgess-SmithPETERHOUSE CAPITAL LIMTED +44 (0)20 7469 0930 Corporate Finance Mark AnwylCorporate Broking Lucy Williams Duncan VaseySTANFORD CAPITAL PARTNERS LIMITED +44 (0)20 3815 8880 Joint Corporate Broker John Howes Patrick ClaridgeCELICOURT COMMUNICATIONS +44 (0)20 8434 2643 Mark Antelme Ollie Mills
Market Abuse Regulation (MAR) Disclosure
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via a